Oncocyte Corp Stock Analysis
| OCX Stock | USD 2.71 0.04 1.50% |
OncoCyte Corp is undervalued with Real Value of 3.28 and Target Price of 4.19. The main objective of OncoCyte Corp stock analysis is to determine its intrinsic value, which is an estimate of what OncoCyte Corp is worth, separate from its market price. There are two main types of OncoCyte Corp's stock analysis: fundamental analysis and technical analysis.
The OncoCyte Corp stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. OncoCyte Corp is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. OncoCyte Stock trading window is adjusted to America/New York timezone.
OncoCyte |
OncoCyte Stock Analysis Notes
About 16.0% of the company outstanding shares are owned by corporate insiders. The book value of OncoCyte Corp was now reported as 0.71. The company recorded a loss per share of 4.44. OncoCyte Corp had not issued any dividends in recent years. The entity had 1:20 split on the 25th of July 2023. OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. To find out more about OncoCyte Corp contact Michael West at 949 409 7600 or learn more at https://www.oncocyte.com.OncoCyte Corp Investment Alerts
| OncoCyte Corp generated a negative expected return over the last 90 days | |
| OncoCyte Corp has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 188 K. | |
| OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: StockNews.com Initiates Coverage on OncoCyte |
OncoCyte Corp Upcoming and Recent Events
Earnings reports are used by OncoCyte Corp to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
OncoCyte Largest EPS Surprises
Earnings surprises can significantly impact OncoCyte Corp's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-12 | 2020-09-30 | -0.09 | -0.1 | -0.01 | 11 | ||
2019-11-14 | 2019-09-30 | -0.09 | -0.1 | -0.01 | 11 | ||
2019-08-14 | 2019-06-30 | -0.09 | -0.1 | -0.01 | 11 |
OncoCyte Corp Environmental, Social, and Governance (ESG) Scores
OncoCyte Corp's ESG score is a quantitative measure that evaluates OncoCyte Corp's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of OncoCyte Corp's operations that may have significant financial implications and affect OncoCyte Corp's stock price as well as guide investors towards more socially responsible investments.
OncoCyte Stock Institutional Investors
| Shares | Advisor Group Holdings, Inc. | 2024-06-30 | 1.1 K | Ubs Group Ag | 2024-06-30 | 835 | Bank Of America Corp | 2024-06-30 | 416 | Jpmorgan Chase & Co | 2024-06-30 | 154 | Piscataqua Savings Bank | 2024-09-30 | 25.0 | Coppell Advisory Solutions Llc | 2024-06-30 | 10.0 | Albion Financial Group (utah) | 2024-06-30 | 7.0 | Td Waterhouse Canada Inc | 2024-06-30 | 1.0 | Qube Research & Technologies | 2024-06-30 | 1.0 | Broadwood Capital Inc | 2024-09-30 | 4.9 M | Pura Vida Investments, Llc | 2024-09-30 | 495.3 K |
OncoCyte Market Capitalization
The company currently falls under 'Micro-Cap' category with a total capitalization of 45.62 M.OncoCyte Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.52) | (1.59) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.09) | (1.14) |
Management Efficiency
OncoCyte Corp has Return on Asset of (0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.59 in 2024. Return On Capital Employed is likely to drop to -0.39 in 2024. At this time, OncoCyte Corp's Other Current Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 15.7 M in 2024, whereas Total Assets are likely to drop slightly above 49.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.35 | 5.55 | |
| Tangible Book Value Per Share | (4.05) | (3.85) | |
| Enterprise Value Over EBITDA | (0.54) | (0.57) | |
| Price Book Value Ratio | 0.75 | 0.71 | |
| Enterprise Value Multiple | (0.54) | (0.57) | |
| Price Fair Value | 0.75 | 0.71 |
OncoCyte Corp showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Operating Margin (55.43) | Beta 1.002 | Return On Assets (0.19) | Return On Equity (1.65) |
Technical Drivers
As of the 23rd of November, OncoCyte Corp holds the Coefficient Of Variation of (1,466), variance of 9.49, and Risk Adjusted Performance of (0.04). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of OncoCyte Corp, as well as the relationship between them.OncoCyte Corp Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. OncoCyte Corp middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for OncoCyte Corp. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
OncoCyte Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OncoCyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on OncoCyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OncoCyte Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OncoCyte Corp Outstanding Bonds
OncoCyte Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. OncoCyte Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most OncoCyte bonds can be classified according to their maturity, which is the date when OncoCyte Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View |
OncoCyte Corp Predictive Daily Indicators
OncoCyte Corp intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of OncoCyte Corp stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
OncoCyte Corp Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 22nd of October 2024 Other Reports | ViewVerify | |
| 18th of October 2024 Other Reports | ViewVerify | |
| 16th of October 2024 Other Reports | ViewVerify | |
F4 | 15th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 9th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
OncoCyte Corp Forecast Models
OncoCyte Corp's time-series forecasting models are one of many OncoCyte Corp's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary OncoCyte Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About OncoCyte Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how OncoCyte Corp prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling OncoCyte shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as OncoCyte Corp. By using and applying OncoCyte Stock analysis, traders can create a robust methodology for identifying OncoCyte entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (16.54) | (17.36) | |
| Operating Profit Margin | (16.72) | (17.56) | |
| Net Loss | (18.48) | (19.41) | |
| Gross Profit Margin | 0.27 | 0.29 |
Current OncoCyte Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. OncoCyte analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. OncoCyte analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 4.19 | Buy | 3 | Odds |
Most OncoCyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand OncoCyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of OncoCyte Corp, talking to its executives and customers, or listening to OncoCyte conference calls.
OncoCyte Stock Analysis Indicators
OncoCyte Corp stock analysis indicators help investors evaluate how OncoCyte Corp stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading OncoCyte Corp shares will generate the highest return on investment. By understating and applying OncoCyte Corp stock analysis, traders can identify OncoCyte Corp position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 23.2 M | |
| Common Stock Shares Outstanding | 7.7 M | |
| Total Stockholder Equity | 25.6 M | |
| Property Plant And Equipment Net | 5.4 M | |
| Cash And Short Term Investments | 9.4 M | |
| Cash | 9.4 M | |
| Accounts Payable | 953 K | |
| Net Debt | -6.6 M | |
| 50 Day M A | 2.9818 | |
| Total Current Liabilities | 7.2 M | |
| Other Operating Expenses | 26.6 M | |
| Non Current Assets Total | 64.2 M | |
| Non Currrent Assets Other | 2.2 M | |
| Stock Based Compensation | 6.6 M |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.